Deregulation of TGF-β1 has been proposed for multiple neurological disorders including AIDS dementia complex, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), MS, anxiety, depression, and schizophrenia (Kashima and Hata, 2018). Here, TGFB1 is linked to amyotrophic lateral sclerosis.